CRBP
NASDAQCorbus Pharmaceuticals Holdings Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$7.38-0.25 (-3.28%)
02:00 PM07:45 PM
News · 26 weeks59+200%
2025-12-072026-05-31
Mix3890d
- SEC Filings17(45%)
- Insider10(26%)
- Other7(18%)
- Earnings2(5%)
- Analyst1(3%)
- Leadership1(3%)
Latest news
25 items- INSIDERChief Business Officer Saxena Nishant C bought $101,218 worth of shares (13,500 units at $7.50), increasing direct ownership by 22% to 75,300 units (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- SECSEC Form S-8 filed by Corbus Pharmaceuticals Holdings Inc.S-8 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- SECCorbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- PRCorbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical CancersData affirms Corbus strategy of targeting tumor types with elevated Nectin-4 expression and clear unmet medical needs while providing an attractive commercial path forward Confirmed ORR of 42.9% observed in 2L oropharyngeal squamous cell carcinoma (OPSCC) at 3.6 mg/kg with median DOR of 6.3 months and PFS of 5.6 months (ongoing)Confirmed ORR of 34.4% observed in 2L cervical cancer at 3.6 mg/kg with median DOR of 8.0 months and PFS of 4.3 months (ongoing)CRB-701 was generally safe and well tolerated with discontinuation rates below 3% About 50% of 2L head and neck cancer cases in the U.S. are HPV-driven OPSCC and receive minimal to no benefit from EGFR-targeted therapiesRegistrational stu
- INSIDERChief Business Officer Saxena Nishant C was granted 58,300 shares, increasing direct ownership by 1,666% to 61,800 units (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- INSIDERNew insider Saxena Nishant C claimed ownership of 3,500 shares (SEC Form 3)3 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- INSIDERDirector Kung Winston was granted 3,800 shares, increasing direct ownership by 37% to 14,166 units (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- INSIDERDirector Jacques Rachelle Suzanne was granted 3,800 shares, increasing direct ownership by 50% to 11,383 units (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- INSIDERDirector Jenkins John Kenneth was granted 3,800 shares, increasing direct ownership by 79% to 8,633 units (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- INSIDERDirector Ben Yong was granted 3,800 shares, increasing direct ownership by 50% to 11,383 units (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- INSIDERDirector Altmeyer Anne was granted 3,800 shares, increasing direct ownership by 61% to 9,991 units (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- INSIDERDirector Pfeiffenberger Brent was granted 7,500 shares (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- INSIDERSEC Form 3 filed by new insider Pfeiffenberger Brent3 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- SECCorbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- PRCorbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference CallNORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that the Company's management team will host a conference call and webcast on Tuesday, May 26 at 8:00 a.m. EDT to discuss updated data for its Phase 1/2 study of CRB-701, a next-generation Nectin-4 antibody drug candidate (ADC), in both head and neck squamous cell carcinoma (HNSCC) as well as cervical cancer. The data, which will be presented at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, represent an April 1, 2026 data cut, and will include cli
- SECCorbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- PRCorbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of DirectorsNORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the appointment of Brent Pfeiffenberger, PharmD, MBA, to the Company's Board of Directors. "Brent is an accomplished pharma industry leader with deep expertise across research, development, and commercialization of life-saving drugs," said Rachelle Jacques, Chair of the Corbus Board of Directors. "His proven record of delivering value-generating commercial successes and steering notable corporate evolutions adds distinctive perspective to the Corbus Board. We look forward to Bre
- PRCorbus Pharmaceuticals to Participate in Upcoming Investor ConferencesNORWOOD, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview and attend investor meetings at both the RBC Capital Markets Global Healthcare Conference being held in New York on May 19 – 20, 2026, and the Jefferies Global Healthcare Conference being held in New York on June 2 - 4, 2026. RBC Capital Markets Global Healthcare ConferenceFormat:Presentation and one-on-one investor meetingsDate:Tuesday, May 19, 2026Time:2:05pm EDTWebcast:Click here Jef
- SECSEC Form 10-Q filed by Corbus Pharmaceuticals Holdings Inc.10-Q - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- SECCorbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- PRCorbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate UpdateReached broad alignment with the FDA on the registration path for CRB-701 for 2L treatment in head and neck squamous cell carcinoma (HNSCC) and cervical cancer with CRB-701Announced presentation of updated CRB-701 data in HNSCC and cervical cancer at ASCO 2026Completed enrollment in 16-week study CANYON-1 study (n=240) of CRB-913 for the treatment of obesity with topline data on track to report this summer NORWOOD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today provided a corporate update and reported financial res
- PRCorbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026NORWOOD, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced that it will host an in-person and virtual KOL event at the 2026 American Society of Clinical Oncology (ASCO) annual meeting to discuss updated data from the Phase 1/2 clinical study of CRB-701 in 75 participants with head and neck squamous cell carcinoma (HNSCC). Data will include clinical response durability as well as HNSCC patient subgroup analysis. These data will be presented as a poster at the 2026 ASCO annual meeting, to be held May 29 – June 2, 2026 in Chicago, IL. The KOL event
- ANALYSTGuggenheim initiated coverage on Corbus Pharma with a new price targetGuggenheim initiated coverage of Corbus Pharma with a rating of Buy and set a new price target of $45.00
- PRCorbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701NORWOOD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced that updated clinical data from its Phase 1/2 study of CRB-701, a next generation Nectin-4 ADC, in both head and neck squamous cell carcinoma (HNSCC) and cervical cancer will be presented at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2 in Chicago, IL. The data will include clinical response durability as well as HNSCC patient subgroup analysis. Corbus previously presented dose optimization data from the study, including encoura
- SECSEC Form DEFA14A filed by Corbus Pharmaceuticals Holdings Inc.DEFA14A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
CRBP FAQ
6 questionsWhat does Corbus Pharmaceuticals Holdings Inc. do?
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as...Where does CRBP stock trade?
Corbus Pharmaceuticals Holdings Inc. (CRBP) is listed on NASDAQ.What sector and industry is CRBP in?
Corbus Pharmaceuticals Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CRBP?
Corbus Pharmaceuticals Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $4500.00 price target on 2026-04-29. Recent price targets range from $2800.00 to $4500.00.What companies are similar to CRBP?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CRBP side-by-side with any of them on Quantisnow.How can I track CRBP on Quantisnow?
Quantisnow aggregates Corbus Pharmaceuticals Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRBP to receive live email and push alerts on every new disclosure.